Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market Program on Nasdaq
DBV Technologies Announces the Filing of its 2026 Half-Year Report - Conditions for Accessing or Consulting the Report
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
CUAI - Copper Intelligence Extensive Drilling Program Continues to Validate Significant Copper System at Butembo, Eastern DRC
Syntholene Completes Phase One of Effects Testing at Iceland Demonstration Facility, Advances to High-Power Operations
